Metformin has been associated with increased survival of ER+/HER2+ breast cancer patients with metabolic dysregulation (type II diabetes) in several studies including the Phase III Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation (ALTTO) trial[124,125]. This evidence concerns the gene ERBB2 and breast carcinoma.